Could a seed protein stop oral cancer? early study hints at promise
NCT ID NCT04188665
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study looked at whether a protein from the Maackia amurensis seed (MASL) can target a receptor called podoplanin found on oral cancer and precancerous cells. Researchers measured how much of this receptor was present in tissue samples from 18 adults with suspicious mouth lesions. The goal was to see if MASL could reduce the receptor's activity and potentially slow cancer growth, but the study focused on understanding the biology rather than proving a treatment works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHROPLAKIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
New Jersey Medical School
Newark, New Jersey, 07103, United States
-
Rowan University
Stratford, New Jersey, 08084, United States
-
Rutgers School for Dental Medicine
Newark, New Jersey, 07103, United States
-
University Hospital
Newark, New Jersey, 07103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid gel quiet oral lichen planus by altering MicroRNAs?
- Smartphone app aims to combat malnutrition in head and neck cancer patients
- Can adding radiation boost immunotherapy against spread head and neck cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- A pharmacist in the dentist's chair: could a new team approach tame stubborn mouth conditions?
- Immunotherapy tackles precancerous mouth spots